HWM
CORT icon

Hemington Wealth Management’s Corcept Therapeutics CORT Stock Holding History

Hemington Wealth Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$12K Buy
155
+10
+7% +$724 ﹤0.01% 803
2025
Q2 		$10K Buy
145
+25
+21% +$1.81K ﹤0.01% 846
2025
Q1 		$13K Buy
120
+46
+62% +$2.8K ﹤0.01% 717
2024
Q4 		$3K Buy
74
+35
+90% +$1.83K ﹤0.01% 1150
2024
Q3 		$1K Buy
+39
New +$1.39K ﹤0.01% 1289

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Hemington Wealth Management's CORT Position: Q3 2025 in Review

Hemington Wealth Management increased its Corcept Therapeutics (CORT) stake by 6.9% in Q3 2025, buying an estimated $724 and bringing the position to 155 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #803.

Hemington Wealth Management first reported a position in CORT in Q3 2024 and has held it in 5 quarters since. The position peaked at $13K in Q1 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • Hemington Wealth Management held 155 shares of Corcept Therapeutics worth $12K as of Q3 2025.
  • Hemington Wealth Management bought 10 Corcept Therapeutics shares in Q3 2025, an estimated $724.
  • Corcept Therapeutics made up ﹤0.01% of Hemington Wealth Management's portfolio in Q3 2025, its #803 holding.
  • Hemington Wealth Management first reported a position in Corcept Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Hemington Wealth Management's Corcept Therapeutics position peaked at $13K in Q1 2025.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.